Radiochemotherapy for brain metastasis: how to define a role for temozolomide.
Weller
Michael
M
D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary; D018288:Carcinoma, Small Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary; D017024:Chemotherapy, Adjuvant; D017322:Clinical Trials, Phase II as Topic; D016371:Cranial Irradiation; D003606:Dacarbazine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D008545:Melanoma / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary; D009062:Mouth Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D009382:Neoplasms, Unknown Primary / Q000188:drug therapy / Q000532:radiotherapy; D012004:Rectal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D012107:Research Design; D000077204:Temozolomide; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide